|
|
Article: RIBI COMPLETES ADJUVANT LICENSE AGREEMENT FOR NEW SMITHKLINE BEECHAM PHARMA ALLERGY VACCINES IN DEVELOPMENT
- Article from:
- PR Newswire
- Article date:
- April 30, 1996
CopyrightCOPYRIGHT 1996 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
HAMILTON, Mont., April 30 /PRNewswire/ -- Ribi ImmunoChem Research, Inc. (Nasdaq: RIBI) announced today that it has completed a license and supply agreement covering the use of Ribi adjuvants in allergy vaccines under development by SmithKline Beecham Pharma GmbH of Munich, Germany. SmithKline Beecham Pharma GmbH is a subsidiary of SmithKline Beecham (SB, NYSE: SBH).
Under the license/supply agreement, Ribi has granted SmithKline Beecham Pharma (SB Pharma) a license to use Ribi adjuvants commercially upon regulatory approval of SB Pharma's allergy vaccines. The license is exclusive for the European Community, Eastern Europe and Canada and co-exclusive for the rest ...